General Information of Drug (ID: DMP6S0L)

Drug Name
KYS-05056 Drug Info
Synonyms KYS-05056; CHEMBL459245; SCHEMBL14417338; BDBM50251382
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44567628
TTD Drug ID
DMP6S0L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [2]
Ethosuximide DMDZ9LT Epilepsy 8A60-8A68 Approved [3]
Trimethadione DM0Q8MZ Absence epilepsy Approved [4]
Paramethadione DMR5ZUP Absence epilepsy Approved [4]
Methsuximide DM6L5VO Absence epilepsy Approved [5]
Penfluridol DMG1DTE Schizophrenia 6A20 Approved [6]
PD-200390 DMPW28M Insomnia 7A00-7A0Z Phase 2 [7]
NGD 94-1 DMM1Y8F Schizophrenia 6A20 Phase 1 [6]
ML218 DM3D21X Discovery agent N.A. Investigative [8]
KYS-05001 DM3MID9 Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) TT729IR CAC1G_HUMAN Inhibitor [1]

References

1 T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901.
2 Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
3 Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
4 Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
5 Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
6 Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
7 Pfizer. Product Development Pipeline. March 31 2009.
8 The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
9 Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.